
Madagascar ALMA Quarterly Report Quarter One, 2024




Scorecard for Accountability and Action



Financing	
LLIN financing (2024-2026) projection (% of need)	95
Public sector ACTs and RTDs financing (2024-2026) projection (% of need)	100
% of National Malaria Strategic Plan Financed (2024- 2026)	74
Policy	
Signed, ratified and deposited the AMA instrument at the AUC	
Malaria activities targeting refugees in Malaria Strategic Plan	
Malaria activities targeting IDPs in Malaria Strategic Plan	
Zero Malaria Starts With Me Launched	
End Malaria Council and Fund Launched	
Resistance Monitoring, Implementation and Impact	
Drug efficacy studies conducted since 2019 and data reported to WHO	
Insecticide classes with mosquito resistance in representative sentinel sites confirmed since 2010	
Insecticide resistance monitored since 2015 and data reported to WHO	
RDTs in stock (>6 months stock)	
ACTs in stock (>6 months stock)	
LLIN/IRS campaign on track	
% of vector control in the last year with next generation materials	(
On track to reduce malaria incidence by at least 75% by 2025 (vs 2015)	
On track to reduce malaria mortality by at least 75% by 2025 (vs 2015)	
Tracer Indicators for Maternal and Child Health and NTDs	
Mass Treatment Coverage for Neglected Tropical Disease (NTD index, %)(2022)	47
% of Neglected Tropical Disease MDAs Achieving WHO Targets	(
Estimated % of children (0–14 years old) living with HIV who have access to antiretroviral therapy (2022)	7
Vitamin A Coverage 2022 (2 doses)	34
DPT3 coverage 2022 (vaccination among 0-11 month olds)	57

Malaria transmission in Madagascar occurs all year round in the north of the country. The annual reported number of malaria cases in 2022 was 1,679,547 with 291 deaths.

Key



Madagascar ALMA Quarterly Report Quarter One, 2024



Malaria

Africa is at the centre of a perfect storm that threatens to disrupt malaria services and undo decades of progress. We must act urgently to both prevent and mitigate the adverse effects of the ongoing global financial crisis, increasing biological threats, climate change, and humanitarian crises. These threats represent the most serious emergency facing malaria in 20 years and will lead to malaria upsurges and epidemics if not addressed. AU Member States face a \$1.5 billion gap just to sustain existing, yet inadequate, levels of malaria-related services between now and 2026. To get back on track and eliminate malaria, we will need to mobilise another \$5.2 billion dollars annually to fully finance our national malaria plans. Climate change presents a significant threat to the progress that we have made. Africa is disproportionately exposed to the risks of climate change and by the 2030s, 150 million additional people will be at risk of malaria because of warmer temperatures and increased rainfall. Climate disasters displace millions and destroy roads and health facilities, reducing access to health services. There is urgency to decarbonise and reduce our carbon footprint. We must implement integrated and multisectoral solutions, and adapt our health systems to the threats of both climate change and pandemics. We must also take action to confront the threats of insecticide and drug resistance, reduced efficacy of rapid diagnostic tests, and the Anopheles stephensi mosquito which spreads malaria in both urban and rural areas. The good news is that the malaria toolkit continues to expand. WHO has approved the use of dual-insecticide mosquito nets that are 43% more effective than traditional mosquito nets and will address the impact of insecticide-resistance. New medicines for treating malaria and two malaria vaccines for children have also been approved with an increasing number of countries deploying these new tools. The scaling up of these interventions will help us achieve our goal of eliminating malaria. This will require integrated approaches with malaria as a pathfinder for pandemic preparedness, climate change and health, Primary Health Care and Universal Health Coverage. We must work to sustain and increase domestic resource commitments including through multisectoral End Malaria and NTD councils and Funds, which have raised over US\$50 million

Progress

Madagascar has secured most of the finances for procurement of the majority of the required LLINs, ACTs and RDTs required for the 2024-20026 period. The country has carried out insecticide resistance monitoring since 2015 and has reported the results to WHO. The country has finalised the insecticide resistance management and monitoring plan and has carried out drug resistance testing since 2018 and has reported the results to WHO.

In line with the priority agenda of the ALMA chair, His Excellency President Umaro Sissoco Embaló, Madagascar has enhanced the tracking and accountability mechanisms for malaria with the development of a Malaria Control and Elimination Scorecard, although this scorecard is not yet shared on the ALMA Scorecard Hub. The country should consider establishing an End Malaria Council and Fund to enhance domestic resource mobilization and multi-sectoral action.

Impact

The annual reported number of malaria cases in 2022 was 1,679,547 with 291 deaths.

Key Challenge

Resource Gaps to Fully Implement the malaria National Strategic Plan

Previous Key Recommended Action

Madagascar has responded positively to the recommended action addressing increased malaria incidence and mortality and continues to track progress as actions are implemented.

Reproductive, Maternal, Newborn, Adolescent and Child Health

Progress

Madagascar has enhanced the tracking and accountability mechanisms with the development of a Reproductive, Maternal, Newborn, Child and Adolescent Health Scorecard.

Previous Key Recommended Actions

The country has responded to the recommended actions to increase coverage of ARTs and vitamin A, and continues to track progress as key actions are implemented.

Neglected Tropical Diseases Progress

Progress in addressing Neglected Tropical Diseases (NTDs) in Madagascar is measured using a composite index calculated from preventive chemotherapy coverage achieved for lymphatic filariasis, schistosomiasis, and soil transmitted helminths. In 2022, preventive chemotherapy coverage was 35% for lymphatic filariasis, 71% for schistosomiasis and 41% for soil transmitted helminthiasis. Overall, the NTD preventive chemotherapy coverage index for Madagascar in 2022 is 47, which represents a very substantial increase compared with the 2021 index value (7). The country did not reach any WHO MDA target in 2022.

